HRP940305A2 - Compositions in the form of solid solutions - Google Patents
Compositions in the form of solid solutions Download PDFInfo
- Publication number
- HRP940305A2 HRP940305A2 HRP4316537.0A HRP940305A HRP940305A2 HR P940305 A2 HRP940305 A2 HR P940305A2 HR P940305 A HRP940305 A HR P940305A HR P940305 A2 HRP940305 A2 HR P940305A2
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- preparations
- coumarin
- polymer
- contain
- Prior art date
Links
- 239000006104 solid solution Substances 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title description 7
- 239000013543 active substance Substances 0.000 claims abstract description 17
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 8
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 8
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims abstract description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 18
- -1 7-hydroxy3,4- dimethylcoumarinethanesulfonic acid Chemical compound 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 150000004775 coumarins Chemical class 0.000 claims description 7
- 239000000155 melt Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- CGMNMWHRKGKEGN-UHFFFAOYSA-N 5-methoxy-3,4-dimethyl-7-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)chromen-2-one Chemical compound C=1C=2OC(=O)C(C)=C(C)C=2C(OC)=CC=1C1=NN=C(C(C)C)S1 CGMNMWHRKGKEGN-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 8
- 235000001671 coumarin Nutrition 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 229960000956 coumarin Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BQSOXIMMJBWKJW-UHFFFAOYSA-N 3,6-dichloro-5-methoxy-4-methyl-7-(2-propan-2-yl-1,3-thiazol-4-yl)chromen-2-one Chemical compound C=1C=2OC(=O)C(Cl)=C(C)C=2C(OC)=C(Cl)C=1C1=CSC(C(C)C)=N1 BQSOXIMMJBWKJW-UHFFFAOYSA-N 0.000 description 1
- ROUXQKJFFLRMRY-UHFFFAOYSA-N 3,6-dichloro-7-(2-cyclopropyl-1,3-thiazol-4-yl)-5-methoxy-4-methylchromen-2-one Chemical compound C=1C=2OC(=O)C(Cl)=C(C)C=2C(OC)=C(Cl)C=1C(N=1)=CSC=1C1CC1 ROUXQKJFFLRMRY-UHFFFAOYSA-N 0.000 description 1
- AZPIEIJAVZYEHN-UHFFFAOYSA-N 3-methoxy-7-(5-methyl-1,3,4-thiadiazol-2-yl)-4-(trifluoromethyl)chromen-2-one Chemical compound C1=C2OC(=O)C(OC)=C(C(F)(F)F)C2=CC=C1C1=NN=C(C)S1 AZPIEIJAVZYEHN-UHFFFAOYSA-N 0.000 description 1
- XOZOYOZAQFJNDN-UHFFFAOYSA-N 5-methoxy-3,4-dimethyl-7-(2-methyl-1,3-thiazol-4-yl)chromen-2-one Chemical compound C=1C=2OC(=O)C(C)=C(C)C=2C(OC)=CC=1C1=CSC(C)=N1 XOZOYOZAQFJNDN-UHFFFAOYSA-N 0.000 description 1
- VRMJEIQMXUOEMB-UHFFFAOYSA-N 5-methoxy-3,4-dimethyl-7-(2-propan-2-yl-1,3-thiazol-4-yl)chromen-2-one Chemical compound C=1C=2OC(=O)C(C)=C(C)C=2C(OC)=CC=1C1=CSC(C(C)C)=N1 VRMJEIQMXUOEMB-UHFFFAOYSA-N 0.000 description 1
- SMDFXLARWLUVHU-UHFFFAOYSA-N 6-bromo-3-chloro-5-methoxy-4-methyl-7-(2-propan-2-yl-1,3-thiazol-4-yl)chromen-2-one Chemical compound C=1C=2OC(=O)C(Cl)=C(C)C=2C(OC)=C(Br)C=1C1=CSC(C(C)C)=N1 SMDFXLARWLUVHU-UHFFFAOYSA-N 0.000 description 1
- JOAYPEDCGXDFRW-UHFFFAOYSA-N 7-(2-benzyl-1,3-thiazol-4-yl)-5-methoxy-3,4-dimethylchromen-2-one Chemical compound C=1C=2OC(=O)C(C)=C(C)C=2C(OC)=CC=1C(N=1)=CSC=1CC1=CC=CC=C1 JOAYPEDCGXDFRW-UHFFFAOYSA-N 0.000 description 1
- WXGHIGGAKRGXCS-UHFFFAOYSA-N 7-(2-cyclopropyl-1,3-thiazol-4-yl)-5-methoxy-3,4-dimethylchromen-2-one Chemical compound C=1C=2OC(=O)C(C)=C(C)C=2C(OC)=CC=1C(N=1)=CSC=1C1CC1 WXGHIGGAKRGXCS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- KFMQPIHLHGRTFB-UHFFFAOYSA-L disodium;2,2-dimethyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)C(C)(C)C(C([O-])=O)S(O)(=O)=O KFMQPIHLHGRTFB-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000004867 thiadiazoles Chemical group 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Jellies, Jams, And Syrups (AREA)
- Cephalosporin Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Ovaj izum odnosi se na nove pripremke u obliku čvrstih otopina koji
a) kao aktivnu tvar sadrže 1 do 90% težinski derivata kumarina A iz skupine heterociklički supstituiranih alkoksikumarina ili hidroksikumarina esterificiranog s jednom sulfonskom kiselinom i
b) kao noseću tvar sadrže 10 do 99% težinski najmanje jednog u vodi topivog polimera B.
Osim toga izum se odnosi na postupak za izradu tih pripremaka kao i na njihovu upotrebu kao lijekova.
Pripremci, u kojima je aktivna tvar homogeno raspodijeljena u polimerima topivim u vodi općenito su poznati u brojnim izradama. U EP-A 240 773, EP-A 462 066, EP 521 310 i Drug Development and Industrial Pharmacy, 6 (2), 137-160 (1980) opisani su primjerice pripremci koji kao noseću tvar sadrže hidroksipropilmetilcelulozu odnosno polivinilpirolidon.
Heterociklički supstituiran alkoksikumarin
[image]
RI, RII, RIII, RIV = supstituenti, Het = heterociklički ostatak koji sadrži N, S i O,
i ester sulfonske kiseline hidrokumarina
[image]
RI, RII, RIII, RIV = supstituenti,
te farmaceutski pripremci koji te tvari sadrže kao aktivne tvari poznati su, i u US-A 5 073 563 predlažu se za liječenje bolesti središnjeg nervnog sustava, osobito neurodegenerativnih oboljenja i Parkinsonove bolesti, odnosno u EP-B 111 746 za liječenje psihičkih poremećaja, osobito depresija. Nedostatak ovih tvari i njihovih tamo opisanih galenskih pripremaka je to da su zbog svoje slabe topivosti u vodi glede njihove biološke podnošljivosti ostavljeni na želju. Stoga se ti derivati kumarina, koji dolaze u kristaliničnom obliku, nakon uzimanja ne resorbiraju potpuno, a i to samo vrlo polako.
U osnovi izuma bila je stoga zadaća staviti na raspolaganje pripremke u obliku čvrste otopine s dobrom topivošću i biološkom raspoloživošću kao i brzom resorpcijom derivata kumarina A.
Prema tome pronađeni su uvodno definirani pripremci.
Nadalje, izum se odnosi na pronalazak postupka za njihovo pripremanje, njihovu upotrebu kao 1jekova, te njihove oblike davanja.
Pripremci u skladu s izumom sadrže
a) 1 do 90% težinski, prvenstveno 10 do 40% tež. derivata kumarina A iz skupine heterociklički supstituiranih alkoksikumarina ili hidroksi kumarina esterificiranih sa jednom sulfonskom kiselinom kao aktivnom tvari i
b) 10 do 99% tež., prvenstveno 60 do 90% tež. barem jednog u vodi topivog polimera B kao noseće tvari.
Kao heterociklički supstituirani alkoksikumarin A' u obzir dolaze spojevi navedeni u US-A 5 073 563, pri čemu ovdje su prikladni prvenstveno oni koji kao heterocikličke supstituente nose tiadiazol-ostatak i koji su traženi u navedenom spisu. Osobito su prikladni
4-trifluorometil-7-(2-metil-1,3,4-tiadiazol-5-il)-metoksi-kumarin,
3,4-dimetil-7-(2-izopropil-1,3, 4-tiadizol-5-il)-metoksi-kumarin,
3,6-diklor-4-metil-7-(2-ciklopropiltiazol-4-il) –metoksi-kumarin,
3,4-dimetil-7-(2-metiltiazol-4-il)-metoksikumarin,
3,4-dimetil-7, (2-feniltiazol-4-il)-metoksikumarin,
3,4-dimetil-7(2-benziltiazol-4-il)-metoksikumarin,
3,4-dimetil-7-(2-izopropiltiazol-4-il)-metoksikumarin,
3,4-dimetil-7-(2-ciklopropiltiazol-4-il)-metoksikumarin,
3,6-diklor-4-metil-7-(2-izopropiltiazol-4-il)-metoksikumarin,
6-brom-3-klor-4-metil-7-(2-izopropiltiazol-4-il)-metoksikumarin .
Kao hidroksikumarini A'' esterificirani sa sulfonskom kiselinom obzir dolaze spojevi opisani u EP-B 111 746.
Posve osobito načelo u skladu s izumom prikladno je za pripremke s 3,4-dimetil-7(2-izopropil-1,3,4-tiadiazol-5-il)-metoksikumarin A'/1
[image]
iz skupine heterociklički supstituiranih alkoksikumarina A' i sa esterom A''/1 7-hidroksi-3,4-dimetilkumarin-etansulfonske kiseline
[image]
iz skupine hidroksikumarina sa esterificiranih sa sulfonskom kiselinom kao aktivnom tvari.
Kao u vodi topivi polimeri B navode se:
- alkilceluloza kao metilceluloza,
- hidroksialkilceluloza kao hidroksimetil-, hidroksietil-, hidroksipropil- i hidroksibutilceluloza,
- hidroksialkilalkilceluloza kao hidroksietilmetil- i hidroksipropilmetilceluloza,
- karboksialkilceluloza kao karboksimetilceluloza,
- alkilmetalna sol karboksialkilceluloze kao natrij -karboksimetilceluloza,
- karboksialkilcelulozni ester,
- N-vinilpirolidon-vinilacetat-kopolimer,
- polivinilpirolidon,
- polivinilalkohol,
- poliakrilna kiselina i njene soli,
- polimetakrilna kiselina i njene soli,
- polialkilenoksidi kao polietilen oksid i polipropilenoksid kao i kopolimeri etilen- i propilenoksida,
- polisaharidi kao alginska kiselina, njihove alkalne i amonijačne soli, karagenani, galaktomanani, tragant, agar-agar, gumirabika, guma guar i ksantan guma,
- derivati kitina kao kitosan,
- pektini kao natrijkarboksimetilamilpektin,
- škrobovi,
te mješavine ovih u vodi topivih polimera.
Kao polimeri B prednost imaju metilceluloza, hidroksipropilmetilceluloza, hidroksipropilceluloza, polivinilpirolidon i N-vinilpirolidon-vinilacetat- kopolimer, osobito polivinilpirolidon i kopolimeri od 40 do 70 % tež. N-vinilpirolidona i 30 do 60% tež. vinilacetata.
Pod topivim u vodi podrazumijeva se da se pri 20°C u 100 g vode topi najmanje 0,5 g, prvenstveno 2 g polimera po potrebi koloidalno odnosno uz stvaranje gela.
Čvrsta otopina postoji onda kad je aktivna tvar raspodijeljena uglavnom molekularno dispergirana u polimernoj matrici (J. Pharm. Sci. 60, 1281-1302, 1971).
Da bi se pripremili pripremci u skladu s izumom, derivat kumarina A može se rastaliti ili izravno ili u obliku fizičke smjese s polimerom B ili se pomiješa s već pripremljenom polimernom talinom.
U ostalom smješavanje derivata kumarina A s talinom provodi se na sam po sebi poznat način u ekstruderima, prvenstveno jednopužnim ili dvopužnim ekstruderima u temperaturnom području između 50 i 200°C. Oblikovanje polimerne taline koja sadrži derivat kumarina A u pripremke u skladu s izumom može se provesti primjerice kalandriranjem ekstrudata po metodi opisanoj u EP-A 240 906, kao i postupkom prerade poznatim iz DE-A 38 30 355, usitnjavanjem ekstrudata pomoću rotirajućih noževa u volumno jednakim komadima sa skrutnutom površinom, a koji se još mogu preoblikovati, i konačno prešanjem u tablete na konvencionalnoj preši za tabletiranje.
Miješanje aktivne tvari s talinom može se provesti također i u za to prikladnim uređajima, s kojima se na uobičajen način prerađuje plastika, npr. kalanderima i kalupima za injekcijsko prešanje.
Za proizvodnju pripremaka u skladu s izumom derivat kumarina A može se također smiješati - otopljen u hlapivom otapalu - s polimernom talinom. Nadalje, mješavina derivata kumarina A i polimera B može se dobiti zajedničkim otapanjem u hlapivom otapalu i konačnim uparavanjem otapala. Ohlađeni ostatak prerađuje se dalje u čvrste oblike za davanje sukladno talini uz oblikovanje u konvencionalnim uređajima.
U pojedinim slučajevima prije oblikovanja može biti svrhovito, kako u obliku taline tako i u obliku otopine, staviti također uključene spojeve npr. sa ciklodekstrinima.na fino razdijeljen porozni noseći materijal kao što je silika gel i napraviti njihove derivate.
Osim toga pripremci u skladu s izumom mogu sadržavati uobičajene farmaceutske pomoćne tvari kao što su punila, klizna sredstva, sredstva za odvajanje od kalupa, sredstva za reguliranje tečenja, omekšivala, bojila i stabilizatore u količinama od pribl. 60% tež. Te i količine navedene u nastavku uvijek se odnose na ukupnu težinu pripremka (=100%).
Kao punila navode se npr. oksidi magnezija, aluminija, silicija i titana te laktoza, manit, sorbit, ksilit, pentaeritrit i njihovi derivati, pri čemu količina punila je pribl. 0,02 do 50, prvenstveno 0,2 do 20% težine.
Kao sredstva za regulaciju tečenja navode se npr. mono-, di- i trigliceridi masnih kiselina dugačkog lanca kao što su C12-,C14-, C16 i C18-masne kiseline, voskovi kao karnauba vosak te lecitin, pri čemu količina je približno 0,1 do 30, prvenstveno 0,1 do 5% težinski.
Kao omekšivala navode se npr. pored niskomolekularnih polialkilenoksida kao polietilenglikol, polipropilenglikol i polietilenpropilenglikol također i viševalentni alkoholi kao propilenglikol, glicerin, pentaeritrit i sorbit te natrijdimetilsulfosukcinat, mono-, di- i triacetat glicerina i ester polietilenglikolsterarinske kiseline.
Pri tome količina omekšivala je približno 0,5 do 15, prvenstveno 0,5 do 5% težinski.
Kao sredstva za podmazivanje navode se npr. stearati aluminija ili kalcija te talk i silikon, pri čemu njihova količina je pribl. 0,1 do 5, prvenstveno 0,1 do 3% težinski.
Kao stabilizatori navode se primjerice svjetlosni stabilizatori, antioksidanti, sredstva koja hvataju radikale i stabilizatori protiv mikroba, pri čemu njihova količina je pribl. 0,01 do 0,05% težinski.
Moguće je primiješati pomoćne tvari u talinu ili otopinu derivata kumarina A i polimera B. Nadalje, pomoćne tvari mogu se obraditi zajedno s derivatom kumarina A u polimernoj talini ili u otopini polimera B. Osim toga mješavine pomoćnih tvari, derivata kumarina A i polimera B mogu se izravno rastaliti ili otopiti zajedno u jednom otapalu. Općenito uobičajeno je zajedno rastaliti fizičku mješavinu pomoćnih tvari, derivata kumarina A i polimera B.
Pripremci u skladu s izumom upotrebljavaju se kao lijekovi u obliku praha, granulata, tableta, pilula, čepića ili stavljeni u kapsule.
Za oralno davanje preporuča se pripremke na uobičajen način prevući sa slojem bojila npr. od titanodioksida i višebojnih pigmenata za poboljšanje izgleda. Za poboljšanje okusa prikladne su prevlake npr. od glukoze, saharoze, ksilita i manita.
Novi pripremci u obliku čvrstih otopina u usporedbi sa sadašnjim stanjem tehnike pokazuju prednost u tome da se derivat kumarina A bolje oslobađa, čime je njegova biološka raspoloživost i resorpcija značajno povećana. Gotovo homogenom razdiobom amorfnog derivata kumarina A u polimernoj tvari nosiocu B postiže se poboljšanje topivosti u usporedbi sa kristaliničnim derivatom kumarina A.
Primjeri 1 do 9
Za proizvodnju pripremaka u skladu s izumom upotrebljavaju se aktivne tvari
A'/1 3,4-dimetil-7-(2-izopropil-lf 3,4-tiadiazol-5-il)-metoksikumarin i
A''/1 ester 7-hidroksi-3,4-dimetilkumarin-etansulfonske kiseline.
Njihova sinteza vrši se po postupcima opisanim u US-A 5 073 563 odnosno EP-B 111 746.
Upotrebljavaju se slijedeći komercijalno dostupni polimeri B: (relativne viskoznosti određene po kapilarnoj metodi ASTM D 2365-72 (Europaisches Arzneibuch, Bd.III., S. 37)):
B/1 Kopolimerizat od 60% težinski N-vinilpirolidona (NVP) i 40% tež. vinilacetata; V = 1,18-1,31 cps (1%-tna otopina u vodi, 25°C) (KollidonR VA64 tvrtke BASF AG).
B/2 Polivinilpirolidon; V = 1,430-1,585 cps (5%-tna otopina u vodi, 25°C) (KollidonR 17PF tvrtke BASF AG).
B/3 Polivinilpirolidon; V = 1,202-1,276 cps (1%-tna otopina u vodi, 25°C) (KollidonR 30 tvrtke BASF AG).
(V = viskoznost)
Kao pomoćne tvari C upotrebljavaju se slijedeće tvari:
C/1 polietilenoksid, [image] = 6000 (LutrolR E6000 tvrtke BASF AG),
C/2 polietilenoksid, [image] = 1500 (LutrolR E1500 tvrtke BASF AG) ,
C/3 laktoza-monohidrat, fino praškasta; prema DAB-u, Ph Eur, BP, USP (tvrtka Meggle).
([image] = srednja molekulna masa, težinsko sredstvo).
Količine derivata kumarina A, polimera B i dijelom pomoćne tvari C, navedene u primjerima 1 do 6 i 9, bile su pomiješane i zatim stavljene u dvopužni ekstruder i ekstrudirane kroz 5 temperaturnih zona od 60 do 130°C. Izlazni polimerni ekstrudat odvodi se u kalander koji se nalazi neposredno iza do ekstrudera, i koji je u plastu valjka prema unutra presvođen udubljenjima i tu se oblikuju tablete od 1000 mg. Dobiju se svjetlo žute, prozirne tablete.
U primjerima 1 do 6 izmjereno je oslobađanje aktivne tvari metodom s lopaticama za miješanje (paddle-metoda prema USP XXI, US-Arzneibuch). Ova ispitna metoda in vitro služi za određivanje brzine otapanja pripremaka koji sadrže aktivnu tvar (npr. tableta).
Pored toga 900 ml 0,1 N solne kiseline s 0,05 mola/litru natrij sulafata bilo je zagrijano na 37°C u posudi od 1 litre s okruglim dnom. Tijekom ispitivanja ispitna tableta od 1000 mg nalazila se je na okruglom dnu posude u sredini ispod lopatice miješalice, koja se je okretala sa 100 okretaja u minuti. Nakon 1 sata trajanja pokusa količina oslobođene aktivne tvari određena je UV-spekroskopski.
U primjerima 7 do 9 bila je određena apsolutna biološka raspoloživost F ispitnom metodom in vivo.
Pod biološkom raspoloživošću F nekog lijeka podrazumijeva se brzina i količina kojom se terapeutski aktivan sastojak oslobađa iz lijeka, resorbira i konačno dođe na mjesto djelovanja. Kod intravenoznih aplikacija biološka raspoloživost iznosi 100%.
Apsolutna biološka raspoloživost F računa se po slijedećoj jednadžbi:
[image]
AUC = e. area undre the curve; površina ispod krivulje koncentracija/vrijeme (krivulja razine plazme),
AUCX = površina ispod krivulje kod proizvoljne aplikacije,
AUCi.v.= površina ispod krivulje kod intravenozne aplikacije.
Kod ispitne metode in vivo davala se je jedanput po 1 tableta sa 300 mg aktivne tvari po psu (Beagle). Tijekom 24 sata u definiranom vremenskom razmaku uzimani su uzorci krvi i određena je koncentracija aktivne tvari.
Pojedinosti tih pokusa kao i njihovi rezultati prikazani su u tablici 1.
Tablica 6
[image]
a) Umješavanje A' sa laktozom (usporedbeni primjer).
b) Smješavanje u talini (usporedbeni primjer).
c) F određeno na jednom psu.
d) Srednja vrijednost za F određeno na psa (računato preko medijana).
* Usporedbni primjer
** Svi oblici dosegli su 100%-tno oslobađanje aktivne tvari nakon najkasnije 8 sati.
Primjer 10
U slijedećem primjeru mjerena je biološka raspoloživost. U tu svrhu ispitana je farmakokinetika sastava ekstrudata (čvrsta otopina, aktivna tvar bila je u amorfna) na psu (Beagle). Postignute razine plazme navedene su u tablici 2. Za usporedbu date su također i vrijednosti dobivene s granulatom (aktivna tvar bila je samljevena, ali prethodno kristalinična).
Sastav ekstrudata (tableta, pribl. 1 g):
[image]
Sastav granulata (kapsule, veličina 0):
[image]
Rezultati su prikazani u tablici 2.
Tablica 2
Razina plazme A''/1 (Esupron) kod pasa Beagle - 400 mg/kg KG Esuprona p.o. dnevno kroz 14 dana.
[image]
*) Vrijednost ispod granice pronalaženja od 0,2 (ng/ml)
Claims (7)
1. Pripremci u obliku čvrstih otopina koji kao aktivnu tvar sadrže
a) 1 do 90% tež. derivata kumarina A iz skupine heterociklički supstituiranih alkoksikumarina ili hidroksikumarin esterificiran s jednom sulfonskom kiselinom i
b) 10 do 99% tež. barem jednog u vodi topivog polimera B kao noseću tvar.
2. Pripremci prema zahtjevu l, koji sadrže
a) 10 do 40% tež. derivata kumarina A i
b) 60 do 90% tež. u vodi topivog polimera B.
3. Pripremci prema zahtjevu 1 ili 2, koji kao derivat kumarina A sadrže 3,4-dimetil-7-(2-izopropil-1,3,4-tiadiazol-5-il)-metoksikumarin ili ester 7-hidroksi3,4-dimetilkumarinetansulfonske kiseline.
4. Pripremci prema zahtjevima 1 do 3, koji kao polimer B sadrže polivinilpirolidon i/ili N-vinilpirolidon-vinilacetat-kopolimer.
5. Postupak za proizvodnju pripremaka sukladno zahtjevima 1 do 4, naznačen time, da se derivat kumarina A pomiješa s talinom ili otopinom polimera B i da se talina ili ostatak nakon uklanjanja otapala dalje prerađuje uz oblikovanje komadića.
6. Upotreba pripremaka u skladu sa zahtjevima 1 do 4 kao lijekova.
7. Prašak, granulat, tablete, pilule, čepići i injekcijske otopine iz pripremaka u skladu sa zahtjevima 1 do 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4316537A DE4316537A1 (de) | 1993-05-18 | 1993-05-18 | Zubereitungen in Form fester Lösungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP940305A2 true HRP940305A2 (en) | 1996-12-31 |
Family
ID=6488330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP4316537.0A HRP940305A2 (en) | 1993-05-18 | 1994-05-17 | Compositions in the form of solid solutions |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5684040A (hr) |
| EP (1) | EP0697867B1 (hr) |
| JP (1) | JPH08510219A (hr) |
| KR (1) | KR960702305A (hr) |
| CN (1) | CN1123524A (hr) |
| AT (1) | ATE209913T1 (hr) |
| AU (1) | AU688328B2 (hr) |
| BR (1) | BR9406414A (hr) |
| CA (1) | CA2163255A1 (hr) |
| CZ (1) | CZ300895A3 (hr) |
| DE (2) | DE4316537A1 (hr) |
| DK (1) | DK0697867T3 (hr) |
| ES (1) | ES2169073T3 (hr) |
| FI (1) | FI955524A0 (hr) |
| HR (1) | HRP940305A2 (hr) |
| HU (1) | HUT73657A (hr) |
| IL (1) | IL109532A (hr) |
| NO (1) | NO954660D0 (hr) |
| NZ (1) | NZ267080A (hr) |
| PL (1) | PL311698A1 (hr) |
| SI (1) | SI9420035A (hr) |
| WO (1) | WO1994026267A1 (hr) |
| ZA (1) | ZA943368B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| JP4997683B2 (ja) * | 2000-09-25 | 2012-08-08 | 日本新薬株式会社 | 医薬固体分散体の製法 |
| EA200301250A1 (ru) * | 2001-06-22 | 2004-06-24 | Пфайзер Продактс Инк. | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры |
| ES2333645T3 (es) * | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
| JP2004534811A (ja) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | ポリマーと薬剤の集合体を含む医薬組成物 |
| WO2003034302A1 (fr) * | 2001-10-15 | 2003-04-24 | Stark Co., Ltd. | Serveur de fourniture de contenu et systeme de fourniture de contenu dote d'un tel serveur |
| KR20040083493A (ko) | 2002-02-01 | 2004-10-02 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형 |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| BR0313428A (pt) * | 2002-08-12 | 2005-06-28 | Pfizer Prod Inc | Composições farmacêuticas de drogas semi-ordenados e polìmeros |
| US7704528B2 (en) * | 2003-05-05 | 2010-04-27 | Isp Investments Inc. | Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability |
| WO2005005401A1 (ja) * | 2003-07-11 | 2005-01-20 | Osaka Industrial Promotion Organization | スルホン酸エステル化合物およびそれを用いた蛍光プローブ |
| WO2005005400A1 (ja) * | 2003-07-11 | 2005-01-20 | Osaka Industrial Promotion Organization | スルホン酸エステル化合物およびそれを用いた蛍光プローブ |
| EP1832281A1 (en) * | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Process for producing a solid dispersion of an active ingredient |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS542316A (en) * | 1977-06-07 | 1979-01-09 | Yamanouchi Pharmaceut Co Ltd | Solid pharmaceutical composition containing nifedipene |
| JPS5446837A (en) * | 1977-09-19 | 1979-04-13 | Kanebo Ltd | Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same |
| BE880713A (fr) * | 1978-12-21 | 1980-06-19 | Sandoz Sa | Nouvelles compositions pharmaceutiques solides a base d'alcaloides de l'ergot de seigle, permettant une liberation controlee de ce principe actif |
| DE3243158A1 (de) * | 1982-11-23 | 1984-05-24 | Basf Ag, 6700 Ludwigshafen | Neue sulfonsaeureester von hydroxycumarinen, ihre herstellung und sie enthaltende arzneimittel |
| JPS6038322A (ja) * | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固形製剤 |
| GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| JP2636265B2 (ja) * | 1987-10-06 | 1997-07-30 | 萬有製薬株式会社 | 脳循環改善剤 |
| DE3830355A1 (de) * | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur herstellung von pharmazeutischen tabletten |
| DE3834860A1 (de) * | 1988-10-13 | 1990-04-19 | Basf Ag | Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
-
1993
- 1993-05-18 DE DE4316537A patent/DE4316537A1/de not_active Withdrawn
-
1994
- 1994-05-03 IL IL109532A patent/IL109532A/xx not_active IP Right Cessation
- 1994-05-09 US US08/545,754 patent/US5684040A/en not_active Expired - Fee Related
- 1994-05-09 DK DK94917601T patent/DK0697867T3/da active
- 1994-05-09 SI SI9420035A patent/SI9420035A/sl unknown
- 1994-05-09 AT AT94917601T patent/ATE209913T1/de not_active IP Right Cessation
- 1994-05-09 HU HU9503296A patent/HUT73657A/hu unknown
- 1994-05-09 ES ES94917601T patent/ES2169073T3/es not_active Expired - Lifetime
- 1994-05-09 CZ CZ953008A patent/CZ300895A3/cs unknown
- 1994-05-09 DE DE59409994T patent/DE59409994D1/de not_active Expired - Fee Related
- 1994-05-09 NZ NZ267080A patent/NZ267080A/en unknown
- 1994-05-09 EP EP94917601A patent/EP0697867B1/de not_active Expired - Lifetime
- 1994-05-09 CN CN94192144A patent/CN1123524A/zh active Pending
- 1994-05-09 AU AU69263/94A patent/AU688328B2/en not_active Ceased
- 1994-05-09 BR BR9406414A patent/BR9406414A/pt not_active Application Discontinuation
- 1994-05-09 WO PCT/EP1994/001489 patent/WO1994026267A1/de active IP Right Grant
- 1994-05-09 PL PL94311698A patent/PL311698A1/xx unknown
- 1994-05-09 JP JP6524942A patent/JPH08510219A/ja not_active Ceased
- 1994-05-09 CA CA002163255A patent/CA2163255A1/en not_active Abandoned
- 1994-05-17 ZA ZA943368A patent/ZA943368B/xx unknown
- 1994-05-17 HR HRP4316537.0A patent/HRP940305A2/hr not_active Application Discontinuation
-
1995
- 1995-11-16 FI FI955524A patent/FI955524A0/fi unknown
- 1995-11-17 KR KR1019950705132A patent/KR960702305A/ko not_active Application Discontinuation
- 1995-11-17 NO NO954660A patent/NO954660D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL109532A0 (en) | 1994-08-26 |
| HUT73657A (en) | 1996-09-30 |
| AU688328B2 (en) | 1998-03-12 |
| BR9406414A (pt) | 1995-12-19 |
| NO954660L (no) | 1995-11-17 |
| DE59409994D1 (de) | 2002-01-17 |
| IL109532A (en) | 1997-11-20 |
| US5684040A (en) | 1997-11-04 |
| NO954660D0 (no) | 1995-11-17 |
| ES2169073T3 (es) | 2002-07-01 |
| CN1123524A (zh) | 1996-05-29 |
| PL311698A1 (en) | 1996-03-04 |
| EP0697867A1 (de) | 1996-02-28 |
| KR960702305A (ko) | 1996-04-27 |
| FI955524A (fi) | 1995-11-16 |
| SI9420035A (en) | 1996-06-30 |
| JPH08510219A (ja) | 1996-10-29 |
| NZ267080A (en) | 1996-11-26 |
| AU6926394A (en) | 1994-12-12 |
| EP0697867B1 (de) | 2001-12-05 |
| WO1994026267A1 (de) | 1994-11-24 |
| CZ300895A3 (en) | 1996-02-14 |
| HU9503296D0 (en) | 1996-01-29 |
| DE4316537A1 (de) | 1994-11-24 |
| CA2163255A1 (en) | 1994-11-24 |
| ATE209913T1 (de) | 2001-12-15 |
| DK0697867T3 (da) | 2002-03-11 |
| ZA943368B (en) | 1995-11-17 |
| FI955524A0 (fi) | 1995-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101156916B1 (ko) | 이마티닙 및 방출 지연제를 포함하는 제약 조성물 | |
| AU2007301742B2 (en) | Pharmaceutical compositions of aripiprazole | |
| HRP940305A2 (en) | Compositions in the form of solid solutions | |
| AU2007316558A1 (en) | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor | |
| KR20150082203A (ko) | 엔잘루타마이드 제제 | |
| PT1753406E (pt) | Formulação e método para comprimidos revestidos | |
| JPH02104A (ja) | 薬物放出速度調節型製剤 | |
| CN106232144B (zh) | 固体分散体 | |
| TW201526921A (zh) | 一種替格瑞洛固體分散體及其製備方法 | |
| KR20180021814A (ko) | 약물을 포함하는 속방성 정제 및 상기 정제의 형성 공정 | |
| Funk et al. | Immediate release 3D printed oral dosage forms: how different polymers have been explored to reach suitable drug release behaviour | |
| KR101503083B1 (ko) | 고형 제제의 제조 방법 | |
| CN101679390A (zh) | 奥美沙坦酯的粉碎结晶 | |
| Semjonov et al. | Interdependence of particle properties and bulk powder behavior of indomethacin in quench-cooled molten two-phase solid dispersions | |
| EA031607B1 (ru) | Фармацевтическая композиция | |
| EP3501506A1 (en) | Pharmaceutical tablet composition comprising brexpiprazole | |
| dos Santos et al. | Eudragit®: A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics. Pharmaceutics 2021, 13, 1424 | |
| CN105726499B (zh) | 一种利伐沙班药物组合物及其制备方法 | |
| TW201609108A (zh) | 醫藥劑型 | |
| CZ298604B6 (cs) | Farmaceutická smes v pevné forme vhodné pro tabletování a obsahující profen | |
| ES2586912T3 (es) | Forma de dosificación que comprende lopinavir no cristalino y ritonavir cristalino | |
| KR101741414B1 (ko) | 크리소스플레놀 c 함유 고체 분산체, 이를 포함하는 약제학적 조성물 및 이의 제조방법 | |
| Bello | Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts | |
| WO2010082855A1 (en) | Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation | |
| Deshmukh | Investigation of injection moulding for novel drug delivery systems. An investigation into the use of injection moulding to produce pharmaceutical dosage forms and to understand the relationship between materials, processing conditions and performance, in particular drug release and stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ODBC | Application rejected |